Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Keisha L. Gibson, MD, MPH
Advertisement
Keisha L. Gibson, MD, MPH, pediatric nephrologist at the University of North Carolina School of Medicine.
Articles by Keisha L. Gibson, MD, MPH
The FDA granted priority review to obinutuzumab for relapsing/steroid-dependent pediatric INS, based on phase 3 INShore remission data
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
2
Youth-onset type 2 diabetes may progress faster, signs easy to miss
3
When one young athlete’s cardiac arrest revealed a family at risk
4
SUID drives widening Black-White infant mortality gap since 2020
5